Abstract B075: Harnessing Tumor-Penetrating Peptides to Modulate the Pancreatic Tumor Immune Microenvironment
Pancreatic ductal adenocarcinoma (PDAC) has a 5-year survival rate of approximately 13% and remains largely resistant to immunotherapy because its dense fibrotic stroma restricts drug penetration, and its immunosuppressive tumor microenvironment (TME) limits anti-tumor immunity. Novel strategies are urgently needed t...